Workflow
Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook

Beta Bionics Inc. (NASDAQ:BBNX) is one of the best hot stocks to invest in. On October 1, Goldman Sachs upgraded Beta Bionics to Buy from Neutral with a price target of 26,whichwasupgradedfrom26, which was upgraded from 18. Goldman Sachs’ analysis of the diabetes technology market shows sustained growth and profitability for Beta Bionics. Earlier in the second quarter of 2025, Beta Bionics saw a significant 54% year-over-year increase in net sales, reaching $23.2 million. This growth was mirrored in patient adoption, with a 5 ...